Editorial Comment to "Primary Resistance to Immune Checkpoint Inhibitor Combination Therapy in Metastatic Renal Cell Carcinoma: Focus on Nivolumab Plus Ipilimumab". (PubMed, Int J Urol) - Sep 30, 2026 - No abstract available
Checkpoint inhibition • Journal • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor
|